Clinical Evaluation of BackStop in Patients Undergoing Ureteroscopic Lithotripsy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02122341|
Recruitment Status : Terminated (Study has halted prematurely as we were not able to meet our target accrual.)
First Posted : April 24, 2014
Results First Posted : May 22, 2019
Last Update Posted : May 22, 2019
|Condition or disease||Intervention/treatment||Phase|
|Kidney Stones||Device: BackStop||Not Applicable|
During ureteroscopic treatment for ureteral stones, lithotripsy, irrigation, and manipulation of the stone often pushes stone away into the kidney itself. This phenomenon is called retropulsion, which is defined as clinically significant retrograde migration of stone or stone fragments. Movement of stones retrograde into the renal pelvis could potentially add and complicate the surgery further. Often scopes need to be changed in order to reach the stone, and chasing these stones will add time to the surgery and require more valuable resources. Furthermore, sometimes a second operation will need to be done when these retropulsed fragments could not be all found and cleaned out.
A number of devices have been developed to prevent such migration including stone baskets and conical devices. These are wire-based devices which have the potential of injuring the ureter. Because of safety concerns and that there is limited data available on the effectiveness of these devices; these are not widely used by urologists. BackStop has recently been developed as another tool to prevent retropulsion. It is a water soluble gel that is injected proximal to the stone. This creates a physical barrier that prevents stone migration during ureteroscopic lithotripsy for ureteral calculus.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||35 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Post FDA-Approval Clinical Evaluation of BackStopTM in Patients Undergoing Ureteroscopic Lithotripsy: A Prospective, Randomized Clinical Trial|
|Study Start Date :||April 2014|
|Actual Primary Completion Date :||June 2016|
|Actual Study Completion Date :||July 2016|
Patients randomized to the Experimental arm will receive the BackStop gel during their ureteroscopic lithotripsy to prevent retrograde migration of stones or stone fragments.
BackStop™ is a FDA approved device. It is intended for use during ureteroscopic lithotripsy to prevent retrograde migration of stones and stone fragments. It is comprised of a solution of a thermosensitive polymer, a purified version of poloxamer 407 having been fractionated in saline. BackStop™, which is injected above the stone, is provided in sterile, pre-filled 2.5ml and 5ml syringes along with and a corresponding injector and a catheter (3F or 5F).
No Intervention: Control
Patients randomized to the control group will not use any devices to prevent retrograde migration of stones and stone fragments during their ureteroscopic lithotripsy.
- Rate of Prevention of Retrograde Stone or Stone Fragment Migration [ Time Frame: At the time of surgery ]Prevention of retrograde stone migration (Yes/No)
- Stone-free Rate [ Time Frame: 2 months ]Presence or absence of residual stone fragments at 2 month follow up after lithotripsy
- Need for Secondary Procedures [ Time Frame: Up to 3 months ]Need for secondary procedures of patients who had stone migration
- Time for BackStop Injection [ Time Frame: Minutes during Surgery ]Time required to deliver BackStop beginning with insertion of BackStop catheter and ending with its removal subsequent to the delivery of BackStop
- Duration of Lithotripsy Procedure [ Time Frame: during surgery ]Duration of Lithotripsy Procedure
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02122341
|United States, California|
|USC Institute of Urology|
|Los Angeles, California, United States, 90089|
|United States, Virginia|
|Urology of Virginia|
|Virginia Beach, Virginia, United States, 23462|
|Principal Investigator:||Matthew Dunn, M.D.||USC Institute of Urology|